First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations

The efficacy of checkpoint inhibitors for non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METΔ14ex) remains controversial. 110 consecutive METΔ14ex NSCLC patients receiving first-line chemotherapy (CHT) and/or immunotherapy (IO) in 10 German centers between 2016–2022 were analyzed. Com...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of cancer (1990) 2024-03, Vol.199, p.113556-113556, Article 113556
Hauptverfasser:	Blasi, Miriam, Kuon, Jonas, Lüders, Heike, Misch, Daniel, Kauffmann-Guerrero, Diego, Hilbrandt, Moritz, Kazdal, Daniel, Falkenstern-Ge, Roger-Fei, Hackanson, Björn, Dintner, Sebastian, Faehling, Martin, Kirchner, Martina, Volckmar, Anna-Lena, Kopp, Hans-Georg, Allgäuer, Michael, Grohé, Christian, Tufman, Amanda, Reck, Martin, Frost, Nikolaj, Stenzinger, Albrecht, Thomas, Michael, Christopoulos, Petros
Format:	Artikel
Sprache:	eng
Schlagworte:	B7-H1 Antigen Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Exons Humans Immunotherapy Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Met exon 14 skipping Mutation TP53 Tumor Suppressor Protein p53 - genetics Tyrosine kinase inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!